The analysis of cyclophosphamide and its metabolites
- PMID: 10469892
The analysis of cyclophosphamide and its metabolites
Abstract
Cyclophosphamide (CP) has been in clinical use for the treatment of malignant disease for over 40 years. CP is inactive until it undergoes complex metabolic pathways leading to the ultimate alkylating agent, phosphoramide mustard, but also to inactive and toxic metabolites. Sensitive and specific methods are now available for the measurement of CP and its enantiomers, its metabolites and their stereoisomers, in biological matrices. An overview is given of the methods of analysis of CP and its metabolites described in literature since 1993 as well as the current knowledge about its metabolism. Five classes of methods are described: (1) thin-layer chromatography-photographic densitometry, (2) high performance liquid chromatography, (3) gas chromatography and gas chromatography coupled to mass spectrometry, (4) phosphorus-31 nuclear magnetic resonance and (5) enantiomeric separation. In each case, sample clean up and preparation are described. Precision and limits of quantification of the assays are indicated. A table summarizes all the analytical methods for assaying each metabolite.
Similar articles
-
Human metabolites and transformation products of cyclophosphamide and ifosfamide: analysis, occurrence and formation during abiotic treatments.Environ Sci Pollut Res Int. 2016 Jun;23(11):11209-11223. doi: 10.1007/s11356-016-6321-1. Epub 2016 Feb 27. Environ Sci Pollut Res Int. 2016. PMID: 26920534
-
Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.J Mass Spectrom. 2004 Mar;39(3):262-71. doi: 10.1002/jms.570. J Mass Spectrom. 2004. PMID: 15039933
-
Cyclophosphamide and related anticancer drugs.J Chromatogr B Biomed Sci Appl. 2001 Nov 25;764(1-2):173-92. doi: 10.1016/s0378-4347(01)00279-1. J Chromatogr B Biomed Sci Appl. 2001. PMID: 11817027 Review.
-
The chemistry of the metabolites of cyclophosphamide.Curr Pharm Des. 1999 Aug;5(8):627-43. Curr Pharm Des. 1999. PMID: 10469895 Review.
-
Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.Cancer Res. 1978 Feb;38(2):408-15. Cancer Res. 1978. PMID: 620410
Cited by
-
Clinical pharmacokinetics of cyclophosphamide.Clin Pharmacokinet. 2005;44(11):1135-64. doi: 10.2165/00003088-200544110-00003. Clin Pharmacokinet. 2005. PMID: 16231966 Review.
-
Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.DNA Repair (Amst). 2007 Aug 1;6(8):1145-54. doi: 10.1016/j.dnarep.2007.03.010. Epub 2007 May 7. DNA Repair (Amst). 2007. PMID: 17485251 Free PMC article.
-
Transient Effects of Cyclophosphamide on Basal Cell Proliferation of Olfactory Epithelia.Chem Senses. 2020 Oct 9;45(7):549-561. doi: 10.1093/chemse/bjaa039. Chem Senses. 2020. PMID: 32531016 Free PMC article.
-
A network of conserved damage survival pathways revealed by a genomic RNAi screen.PLoS Genet. 2009 Jun;5(6):e1000527. doi: 10.1371/journal.pgen.1000527. Epub 2009 Jun 19. PLoS Genet. 2009. PMID: 19543366 Free PMC article.
-
Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis.Mol Cancer Ther. 2016 Dec;15(12):3000-3014. doi: 10.1158/1535-7163.MCT-16-0271. Epub 2016 Sep 16. Mol Cancer Ther. 2016. PMID: 27638861 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous